ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0098

Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus

Alain Sanchez-Rodriguez1, Jose A Meade-Aguilar2, Jeffrey X. Yang2, Gabriel Figueroa Parra2, Shirley-Ann Osei-Onomah2, Rachel Giblon3, Hannah Langenfeld4, Alanna Chamberlain2, Cynthia Crowson5 and Ali Duarte-Garcia2, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, Rochester, MN, 4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 5Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Access to care, Damage Index, Disease Activity, Disparities, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Delays in access to specialized care and diagnosis of systemic lupus erythematosus (SLE) are associated with poor outcomes. Prior studies rely mostly on cross-sectional surveys and are probably subjected to recall bias. Moreover, Insufficient data from population-based SLE cohorts in the United States limits our understanding of delays to care. We aimed to (1) assess delays to access specialized care and diagnosis, (2) Identify characteristics associated with delays among patients with SLE.

Methods: We assembled a retrospective population-based cohort of adults with incident SLE from 1976 to 2018 in a 27-county region from the American Upper Midwest. All patients met the 2019 EULAR/ACR SLE criteria. Through medical records review, we identified the first medical contact where a manifestation attributed to SLE was noticed and mapped the patient’s trajectories and time to 1) first visit in specialized care (with rheumatology, dermatology, or nephrology) and 2) physician-diagnosed SLE. Disease activity (SLEDAI-2k) and SLICC/ACR damage indexes (SDI) were assessed at the classification date. Those patients who reached specialized care or were diagnosed ≥ 6 months after the first medical encounter were considered to have a delay. We compared demographics, first specialty seen and first clinical feature, SLEDAI, and SDI scores between groups with and without delays.

Results: A total of 350 incident SLE patients were included. Mean age (SD) was 42.8 years (18.4), and 81% were female. The majority of the patients were non-Hispanic White (84%). To access SLE-specialized care, median intervals from the first clinical contact were 1.6 months (IQR 0.3-14), and 3 clinical encounters (IQR 2-4) with 32% delays in access. Patients with delays in access had fewer years of education 13.0 (SD 3.0) vs.13.8 (SD 2.4), (p=0.028), oral ulcers (p=0.0036) and positive antiphospholipid antibodies (aPL) as first feature (p< 0.001) and higher damage score [mean SDI 0.5 (SD 0.8) vs. 0.2 (SD 0.4), (p< 0.01)]. The median time from first clinical contact to diagnosis was 8.3 months (IQR 1.4-58.2). Before receiving a diagnosis, patients needed a median of 2 specialties (IQR1-4), and 6 clinical encounters (IQR 3-13), with 65% having delays. Diagnostic delays were more frequent in Asians (p=0.005) and were less likely to debut with symptoms of abrupt onset (e.g., fever and malar rash) but had more cases of subacute/discoid lupus (p=0.006) and positive aPL (p=0.016) during first contact. Patients first assessed by primary care specialties had delays in diagnosis more frequently compared to those seen first by emergency medicine (p=0.005). This group also had lower disease activity [mean SLEDAI 6.3 (SD 5.0) vs 8.0 (SD 5.6), (p< 0.01)] but higher damage scores [mean SDI 0.4 (SD 0.6) vs. 0.1 (SD 0.2), (p< 0.01)] than those with early diagnosis. (Table 1)

Conclusion: One out of 3 patients had delayed access to specialized care, and two in three had delays in diagnosis. Delays were associated with disparities in race and education, but also with specific features during first contact and increased damage at classification date. Targeted efforts to improve early recognition and referral may prevent irreversible damage and improve the long-term prognosis of SLE.

Supporting image 1

Table 1. Demographic, specialties, and clinical features are stratified according to specialized-care access and diagnosis delays.


Disclosures: A. Sanchez-Rodriguez, None; J. Meade-Aguilar, None; J. Yang, None; G. Figueroa Parra, None; S. Osei-Onomah, None; R. Giblon, None; H. Langenfeld, None; A. Chamberlain, None; C. Crowson, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Sanchez-Rodriguez A, Meade-Aguilar J, Yang J, Figueroa Parra G, Osei-Onomah S, Giblon R, Langenfeld H, Chamberlain A, Crowson C, Duarte-Garcia A. Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/delays-in-access-to-specialized-care-and-diagnosis-in-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/delays-in-access-to-specialized-care-and-diagnosis-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology